Do you want to read an article? Please log in or register.
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study
Macular Diseases
Related content
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
Macular DiseasesRetinal Diseases
Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group
Ophthalmology.
Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), Domalpally A, Clemons TE, Danis RP, Sadda SR, Cukras CA, Toth CA, Friberg TR, Chew EY
doi: 10.1016/j.ophtha.2016.12.004.
Macular DiseasesRetinal Diseases
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Br J Ophthalmol.
Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group
doi: 10.1136/bjophthalmol-
COMMENTED
Macular Diseases
Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients
Acta Ophthalmol.
Mottet B, Aptel F, Geiser MH, Hera R, Zhou T, Almanjoumi A, Vinh V, Chiquet C
doi: 10.1111/aos.13763.
RECOMMENDED
Further Publications
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
JAMA Ophthalmol
Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wykoff CC, Prenner JL, Boyer DS
doi: 10.1001/jamaophthalmol.2021.0221
Macular Diseases
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Ophthalmology.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL
doi: 10.1016/j.ophtha.2019.08.023.
Macular Diseases
One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis
Acta Ophthalmol.
Guo MY, Cheng J, Etminan M, Zafari Z, Maberley D
doi: 10.1111/aos.13825.
Macular Diseases
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab
JAMA Ophthalmol.
Parikh R, Avery RL, Saroj N, Thompson D, Freund KB
doi: 10.1001/jamaophthalmol.2019.1947.
Macular Diseases
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Br J Ophthalmol.
Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F
doi: 10.1136/bjophthalmol-2019-314251.